- Autori: Rebecca L. Haffajee, J.D., Ph.D., M.P.H., Richard G. Frank, Ph.D.
- Journal: N Engl J Med
- Data Publication : 2020; 382:496-498
- DOI1: https://www.nejm.org/doi/full/10.1056/NEJMp1906680
Only about 20% of the more than 2 million Americans with an opioid use disorder (OUD) receive treatment in a given year, much of which is not evidence-based.1 Buprenorphine, one of several medications used to treat OUD, substantially reduces the risk of overdose and can be delivered in office-based settings. Various barriers impede widespread access to buprenorphine, however, including federal requirements that clinicians obtain a waiver to prescribe it. In addition, high prices for brand-name buprenorphine formulations strain the budgets of public programs, which cover a disproportionately large share of people with OUD. In 2017, Medicare and Medicaid were responsible for 32% of the $2.58 billion in prescription buprenorphine sales. The bulk of these sales was for Suboxone, a patent-protected buprenorphine–naloxone sublingual film made by Reckitt Benckiser Pharmaceuticals (now separated from its former parent company and known as Indivior).